Pulmonary Disease, Chronic Obstructive: all 4,252 studies

Page 13 of 43. Open to participants first (707), then studies with results posted, then the rest; newest registration first within each.

• PT003 MDI Dose Confirmation StudyCompletedNCT01349816Phase 2Results posted
• PT003 MDI Cardiovascular Safety StudyCompletedNCT01349803Phase 2Results posted
• In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory InsufficiencyCompletedNCT01347931Not applicableResults posted
• A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))CompletedNCT01342913Phase 3Results posted
• Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety PopulationCompletedNCT01337336Results posted
• A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPDCompletedNCT01336608Phase 3Results posted
• Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance TherapiesCompletedNCT01332461Results posted
• Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationCompletedNCT01332097Phase 2Results posted
• Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01331694Results posted
• Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)CompletedNCT01329029Phase 4Results posted
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study ACompletedNCT01328444Phase 3Results posted
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study BCompletedNCT01323660Phase 3Results posted
• Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01323634Phase 3Results posted
• Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01323621Phase 3Results posted
• A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01322594Phase 1Results posted
• 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseCompletedNCT01316913Phase 3Results posted
• 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseCompletedNCT01316900Phase 3Results posted
• A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01316887Phase 3Results posted
• QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01315249Phase 3Results posted
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01313676Phase 3Results posted
• A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPDCompletedNCT01313650Phase 3Results posted
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPDCompletedNCT01313637Phase 3Results posted
• SMS Reminder to Assess AdherenceCompletedNCT01308476Results posted
• Reliability, Sensitivity and Validity of the 6 Minute Step Test in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01298661Not applicableResults posted
• Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01294787Phase 3Results posted
• Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)CompletedNCT01293006Phase 1Results posted
• Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01285492Phase 3Results posted
• Effectiveness of Incorporating Tai Chi in Pulmonary Rehabilitation Program for Chronic Obstructive Pulmonary Disease Patients in Primary Health CareCompletedNCT01259245Not applicableResults posted
• A Study in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01245569Phase 3Results posted
• A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01233232Phase 2Results posted
• 12-week Open-label Evaluation of Efficacy and Safety of IndacaterolCompletedNCT01232894Phase 3Results posted
• A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01227278Phase 2Results posted
• Tiotropium Respimat Pharmacokinetic Study in COPDCompletedNCT01222533Phase 2Results posted
• Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01218126Phase 2Results posted
• AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)CompletedNCT01215279Phase 2Results posted
• High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)CompletedNCT01214200Not applicableResults posted
• The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01205269Phase 2Results posted
• A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01202188Phase 3Results posted
• A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPDCompletedNCT01192191Phase 3Results posted
• Prophylactic Efficacy of Relenza Against Influenza A and BCompletedNCT01156701Results posted
• Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01154127Phase 3Results posted
• Relative Bioavailability of Olodaterol and FluconazoleCompletedNCT01153724Phase 1Results posted
• Relative Bioavailability of of Olodaterol and KetoconazoleCompletedNCT01153711Phase 1Results posted
• Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01153321Phase 2Results posted
• Effectiveness of Standardized Respiratory Physiotherapy in Primary Care (FREAP)CompletedNCT01152762Not applicableResults posted
• Evaluating Forced Oscillation Technique (FOT) in Abolishing Flow LimitationCompletedNCT01151618Not applicableResults posted
• Adjusting to Chronic Conditions Using Education, Support, and SkillsCompletedNCT01149772Not applicableResults posted
• Drug Use Survey of RESPIMAT in Patients With COPDCompletedNCT01145053Results posted
• IVR-Enhanced Care Transition Support for Complex PatientsCompletedNCT01135381Not applicableResults posted
• Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseCompletedNCT01126437Phase 3Results posted
• Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPDCompletedNCT01125098Results posted
• Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01124422Phase 4Results posted
• A Study to Assess the Long-term Safety of QVA149CompletedNCT01120717Phase 3Results posted
• Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsCompletedNCT01120691Phase 3Results posted
• Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT01120093Phase 2Results posted
• Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01119950Phase 2Results posted
• Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese PatientsCompletedNCT01119937Phase 3Results posted
• Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary DiseaseCompletedNCT01110252Not applicableResults posted
• Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization StudyCompletedNCT01110200Phase 4Results posted
• A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01108835Not applicableResults posted
• Stepping up to Health - for Veterans With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01102777Not applicableResults posted
• Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01089127Phase 3Results posted
• Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01085045Phase 2Results posted
• Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol FumarateCompletedNCT01078623Phase 2Results posted
• 12-week Efficacy of IndacaterolCompletedNCT01072448Phase 3Results posted
• Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary DiseaseCompletedNCT01072396Phase 4Results posted
• A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to PlaceboCompletedNCT01072149Phase 3Results posted
• A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in JapanCompletedNCT01070784Phase 3Results posted
• Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01069289Phase 3Results posted
• Comparison of Efficacy of Indacaterol Versus Placebo Over 12 WeeksCompletedNCT01068600Phase 3Results posted
• Simvastatin Therapy for Moderate and Severe COPDTerminatedNCT01061671Phase 3Results posted
• Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01054885Phase 3Results posted
• Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01054170Phase 2Results posted
• A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01053988Phase 3Results posted
• Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and PlaceboCompletedNCT01049360Phase 2Results posted
• Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®CompletedNCT01048333Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01047553Phase 3Results posted
• Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)CompletedNCT01045161Phase 3Results posted
• Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)CompletedNCT01044459Phase 3Results posted
• Outlook Quality of Life Intervention StudyCompletedNCT01044290Not applicableResults posted
• Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry IICompletedNCT01040793Phase 3Results posted
• A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01040728Phase 3Results posted
• Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01040689Phase 3Results posted
• Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01040403Phase 2Results posted
• Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry ICompletedNCT01040130Phase 3Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPDCompletedNCT01039675Phase 2Results posted
• Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an ExampleCompletedNCT01036763Results posted
• A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01033487Phase 2Results posted
• 28-day Repeat Dose Study of GSK573719CompletedNCT01030965Phase 2Results posted
• Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/FormoterolCompletedNCT01023516Phase 2Results posted
• Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01019694Phase 3Results posted
• A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01017952Phase 3Results posted
• Effect of Indacaterol on Inspiratory Capacity (IC)CompletedNCT01012765Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01009463Phase 3Results posted
• Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European RegionCompletedNCT01006135Results posted
• A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus PlaceboCompletedNCT01005901Phase 3Results posted
• Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01001494Phase 3Results posted
• Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory CapacityCompletedNCT00999908Phase 3Results posted
• A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary DiseaseCompletedNCT00995475Phase 4Results posted
• Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00984659Phase 4Results posted

← Pulmonary Disease, Chronic Obstructive overview